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INTRODUCTION
Viral hepatitis constitutes a major pub-
lic health problem in developing coun-
tries, including India. In addition to par-
enterally transmitted hepatitis B and C
viruses, which cause majority of hepati-
tis, enterically transmitted hepatitis E
virus (HEV) infection is mainly responsi-
ble for sporadic as well as large water-
borne hepatitis epidemics related to poor
hygiene and sanitation. HEV-induced
viral hepatitis is the most common cause
of death in Indian pregnant women (1).
Studies carried out in Iran, Africa, the
Middle East, and other Asian countries
have also found a high mortality due to
fulminant hepatic failure (FHF) during
pregnancy in women with HEV infection
(2–5). In contrast, reports from the
United States and Europe have failed to
find any significant correlation between
death during pregnancy and viral hepa-
titis (6). The mortality rate in pregnant
women with FHF has been found to be
specifically higher during second and
third trimesters of pregnancy (1,2,7–9),
which are associated with an altered sta-
tus of hormones and immunity, but what
exactly influences high mortality during
pregnancy is not known.
NF-kB, a eukaryotic dimeric transcrip-
tion factor formed by hetero- or homod-
imerization of proteins of the Rel family,
is involved in a wide range of cellular
effects, including immune and inflamma-
tory responses, proliferation, cell sur-
vival, and apoptotic stimuli (10). Differ-
ent members of the Rel family, such as
p50, p52, p65, cRel, and RelB possess a
rel homology domain that confers DNA
binding and protein dimerization proper-
ties (11). NF-kB remains in an inactive
form in the cytoplasm by binding to the
labile cytoplasmic inhibitor IκB (12,13),
which masks the RelA nuclear localiza-
tion signal. The release of IκB in response
to intracellular signals leads to nuclear
translocation of the p50 and p65 subunits
and subsequent activation of a whole
set of NF-kB responsive effector genes.
Disruption of the RelA locus in mice
lacking the p65 subunit of NF-kB has
been demonstrated to lead to embryonic
lethality at 15-16 d of gestation due to
massive degeneration of the fetal liver
by programmed cell death (14). Studies
done with p65 knock-out mice also indi-
cated that p65 is indispensable for liver
development and causes enhanced cell
proliferation during embryonic develop-
ment (9). This finding prompted us to in-
vestigate the probable role of NF-kB dur-
ing the death of hepatitis virus infected
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pregnant women with FHF. We report that
the suppression of p65 expression appears
to be associated with the breakdown of
immunity and with severe liver degenera-
tion leading to death of the patient.
MATERIALS AND METHODS
Study Subjects
Heparinized peripheral venous blood
was collected from 25 female patients
(age 20-35 years) with FHF comprising
20 pregnant and five nonpregnant
women. Ten pregnant healthy women
without liver disease and matched for
age, parity, and trimester served as con-
trols. An additional disease control
group comprising five pregnant women
with acute viral hepatitis (AVH) due to
HEV infection was also included. All the
women were in the third trimester of
their pregnancy and were admitted con-
secutively for treatment of hepatic liver
failure during the period from July 2004
to January 2005. Of the 20 pregnant
women with FHF, 15 were infected with
HEV and five were infected with either
HBV or HCV, but all five nonpregnant
FHF and five pregnant AVH patients
were infected with HEV only (Table 1).
Postmortem liver biopsies were collected
from 18 patients who died during the
study. Informed consent was obtained
from all the patients and controls. For
the postmortem biopsy, written consent
was obtained from their immediate rela-
tions. The patients included were either
admitted to Lok Nayak hospital, New
Delhi, or followed up by the hospital’s
outpatient services. Only two patients
who survived were kept on long-term
follow-up until a clinical and biochemi-
cal recovery was achieved and the out-
come of hepatitis virus infection was as-
sessed. Only those patients who were
found to be positive for HEV, HCV, or
HBV and did not have any other serious
diseases were recruited for the study.
All women recruited had undergone
clinical assessment, a urine test for
human chorionic gonadotropin, and
pelvic ultrasound examination for diag-
nosis of pregnancy and duration of ges-
tation. In pregnant women, a careful
clinical assessment, hematological and
biochemical investigations, and liver im-
aging were performed to further define
whether liver disease unique to preg-
nancy could be the cause of acute liver
failure (ALF). Fulminant hepatitis was
considered in patients with no history of
preexisting liver disease who suffered
typical acute-onset hepatitis with severe
liver injury and then became deeply
jaundiced and went into hepatic en-
cephalopathy within 8 wk of the onset
of the disease with no past history of liver
disease (15). AVH was considered in pa-
tients who had suffered acute self-limiting
disease and a serum aminotransferases
(ALT and AST) elevation of at least five-
fold or jaundice, or both. We also ob-
tained five normal liver biopsy speci-
mens from patients who had undergone
abdominal surgeries at Lok Nayak 
Hospital for conditions other than liver
problems and had normal viral markers
for hepatitis viruses and normal liver
function tests. We obtained informed
consent from these patients.
Serology and RT-PCR
The sera from approximately 10 mL of
patient blood was separated and stored
at –70 °C for subsequent viral assays. All
sera collected during the acute phase of
illness were tested for markers of HAV
(IgM anti-HAV), HBV (HBsAg and IgM
anti-HBc), and HCV (anti-HCV s genera-
tion) with commercially available en-
zyme-linked immunosorbent assay
(ELISA) kits, strictly following manufac-
turer instructions. All sera were also
tested for IgM and IgG antibodies to HEV
with an ELISA kit that uses two recombi-
nant HEV antigens corresponding to
structural region of the HEV (Dignostic
Biotechnology, Singapore) (16,17). DNA
and RNA were extracted from the serum
samples of all the patients and employed
for detection of HEV and HCV RNA by
RT-PCR and HBV DNA by PCR using
standard procedures routinely followed
in our laboratory (18). On the basis of the
above viral markers, AVH was classified
as hepatitis A (presence of IgM anti-
HAV), or acute hepatitis B (presence of
HBsAg and IgM anti-HBc). Hepatitis E
was diagnosed by the presence of IgM
anti-HEV (n = 11) and/or HEV RNA (n =
4) in acute phase sera or seroconversion to
Table 1. p50 and p65 Expression of NF-kB Components and the Type of Hepatitis Virus Infection in Pregnant and Nonpregnant Fulminant
Hepatic Failure Patients and Controls.
Sr. Total Virus Type of 
aStatus of
No. Patient type and number No. infection Hepatitis p50 p65
1 Pregnant women 15 HEV FHF + + + -
Pregnant Women 3 20 HBV FHF + + + -
Pregnant Women 2 HCV FHF + + + -
2 Pregnant women (disease control) 5 5 HEV AVH + + + / + + + + / +
3 Nonpregnant women 5 5 HEV FHF + + + +
4 Healthy pregnant women 10 10 Nil Nil + + + + / +
5 Pregnant FHF patients recovered 2 2 Not detected No symptoms + +
aLevel of expression compared to normal controls on the basis of densitometric analysis data;+ + +, high expression; + +, moderate
expression;+, low expression; -, no expression.
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IgG anti-HEV alone in convalescent sera
(16,17). Presence of anti-HCV (n = 1) and
HCV RNA (n = 2) was taken as evidence
of hepatitis C infection.
Preparation of Nuclear Extract and
Western Blot Analysis
Frozen liver biopsies were minced
finely and immediately processed for
preparation of nuclear extract using
previously described methods (19). The
blood samples collected were also imme-
diately processed for nuclear extract
preparation using the same protocol as
for tissue biopsies but with the excep-
tion that peripheral blood mononuclear
cells (PBMCs) were first separated from
whole blood using Histopaq solution
(Sigma, St. Louis, MO, USA) and then
processed for protein extraction. Western
blot analysis was carried out as de-
scribed earlier (19,20). The bands were
visualized with an anti-rabbit IgG anti-
body (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) conjugated with
horseradish peroxidase in a dilution of
1:10000, using the Santa Cruz Luminol
detection kit. To confirm equal protein
loading, Ponceau red staining was used
and in addition, the filters were reincu-
bated, after stripping, with a polyclonal
actin antibody raised against a peptide
mapping at the carboxy terminus of a
normal actin gene of human origin in a
dilution of 1:1000 (Santa Cruz Biotech-
nology, Cat No. sc-1615). The bands
were visualized and quantitated using
the BioRad Gel Doc 2000TM gel docu-
mentation system with Quantity One
Quantitation Software (BioRad Labora-
tories, Hercules, CA, USA). The densito-
metric analysis of fold increase in the
level of expression was calculated in
comparison to that of normal controls.
The densitometric value of actin was
used to normalize the signal. The blots
were stripped of and reincubated with
different antibodies when required.
Stripping of antibody was done by the
standard method of incubating the
membranes in a buffer containing 2%
SDS, 62.5 mM TrisCl, pH 6.8, and 0.1 M
β-mercaptoethanol for 30 min.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay
(EMSA) was carried out using previ-
ously described techniques (19). For
EMSA, the following oligonucleotides
were used: an NF-kB consensus sequence
5′-AGTTGAGGGGACTTTCCCAGGC-3′
and an Oct-1 consensus oligonucleotide
primer 5′-TGTCGAATGCAAATCACTA-
GAA-3′. The antibodies used were: NF-kB
p50 Ab, an epitope corresponding to the
nuclear localization signal region of NF-kB
p50 of human origin (Cat No. sc-114) and
NF-kB p65 Ab, an epitope corresponding
to the amino terminus of NF-kB p65 of
human origin (Cat No. sc-7151, Santa
Cruz Biotechnology). The dried gels
were visualized and bands were quanti-
tated using a BioRad Gel Doc 2000TM gel
documentation system with Quantity One
Quantitation Software (BioRad).
Immunohistochemical Analysis
Immunohistochemistry was also car-
ried out using the previously described
protocol (21). Briefly, after deparaffniza-
tion and rehydration, the tissue sections
were blocked in 3% bovine serum albu-
min for 30 min and incubated overnight
at 37°C with the primary antibody. Im-
munoreactivity was visualized using an
ABC Staining System Kit from Santa
Cruz Biotechnology following the manu-
facturer’s protocol. The slides were then
counterstained regressively in Mayer’s
hematoxylin, dipped in methanol for a
few seconds, cleared in xylene, and
mounted in Permount. To assess the
specificity of staining, sections were
processed without primary or without
secondary antibodies as controls. The
same antibodies were used for the im-
munohistochemical study.
RESULTS
Of the 20 pregnant women with FHF,
15 were infected with HEV, three with
HBV, and two with HCV, as revealed by
both ELISA and PCR tests. The age of
the patients ranged from 20-35 years.
Postmortem liver biopsies were collected
from 18 patients who died during the
study. Two patients recovered following
treatment. Ten healthy pregnant women
constituted the control group, and an
additional disease control group con-
sisted of five pregnant women with
AVH. The details of hepatitis viral infec-
tion, disease, and NF-kB p50 and p65
status are presented in Table 1.
Constitutive Activation and High
Binding Activity of NF-kB in Pregnant
Women with FHF
The DNA binding activity of NF-kB in
FHF patients, as revealed by EMSA in
nuclear extracts obtained from both
PBMCs and postmortem liver biopsies
demonstrated a very high binding activ-
ity of NF-kB in both pregnant and non-
pregnant women (Figure 1; lanes d, e,
Figure 1. Gel shift analysis using nuclear
extracts from PBMC proteins of different
subjects with 32P-labeled oligonucleotide
probe harboring an NF-kB consensus se-
quence. Very low NF-kB binding activity
was observed in the healthy pregnant
women (lane a), a moderate level of
binding activity was observed in disease
control (pregnant women with AVH)
(lanes b and c), while a very high binding
activity was observed in the hepatitis virus
infected FHF patients, both nonpregnant
(lane d) and pregnant (lane e and f). The
positions of the specific retarded bands
are indicated. The squares mark the un-
specific complexes. The extent of binding
activity as revealed by densitometry anal-
ysis is indicated below each lane.
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and f) with FHF due to hepatitis virus
infection. In contrast, 8 of 10 women in
the healthy control group showed very
low binding activity (Figure 1; lane a).
Two healthy controls, however, showed
moderately higher NF-kB binding activ-
ity. Women in the disease control group
(pregnant women with AVH) also
showed a moderate level of NF-kB bind-
ing activity (Figure 1; lanes b and c). The
extent of binding activity as revealed by
densitometric analysis is indicated below
each lane (see Figure 1). All of the preg-
nant women infected with HBV, HCV, or
HEV showed very high NF-kB binding
activity. The binding was found to be
specific, because the retarded complex
disappeared after competition with a
100-fold molar excess of a homologous
(NF-kB), but not with a heterologous,
cold probe containing the consensus se-
quence for the transcription factor Oct-1
(Figure 2A). The specificity of NF-kB
binding was reconfirmed in a separate
band shift assay in which we used la-
beled consensus sequence of Oct-1 as a
probe (Figure 2B).
Absence of p65 Component in NF-kB
Complex Formation in Pregnant FHF
Patients
For further dissection of the NF-kB
complex, band supershift experiments
were carried out using antibodies raised
against p50 and p65 components of 
NF-kB. In the normal healthy pregnant
women who showed low or moderate
levels of NF-kB binding activity, both
p50 and p65 were involved in binding
activity and complex formation, al-
though p50 was the major component
(Figure 3A). Most interestingly, we ob-
served complete absence of p65 in dimer
formation in pregnant females with FHF.
It appears that p50 formed a homodimer,
because all of the p50 but none of the
p65 was supershifted (see Figure 3B, C).
A similar pattern of differential binding
activity of NF-kB was also observed in
postmortem liver biopsy specimens from
18 pregnant women who died (Figure 4A).
All cases of FHF in pregnant women re-
vealed the absence of p65 in dimer for-
mation in both PBMCs and liver tissues.
In the two women who recovered, how-
ever, some p65 participation in the bind-
ing complex of NF-kB was observed, but
to a much lesser extent (Figure 3 D, E).
SELECTIVE SUPPRESSION OF p65
PROTEIN EXPRESSION IN PREGNANT
FHF PATIENTS
When we analyzed the expression pro-
file of p50 and p65 at the protein level by
immunoblotting, we observed that all
pregnant women with FHF also showed
a moderate to high level of p50 expres-
sion while p65 was completely absent or
present in a negligible amount (Table 1,
Figure 5). The same pattern of expression
of NF-kB components was also observed
in the postmortem liver biopsy speci-
mens of FHF pregnant females who died
after being admitted to the hospital 
(Figure 4B). To rule out the possibility 
of cytoplasmic localization of p65 in liver
tissues of pregnant women with FHF,
immunohistochemical analysis was car-
ried out for in situ visualization, and it
was very clear from the immunohisto-
chemical staining that p65 expression
was neither cytoplasmic nor nuclear in
the postmortem liver biopsies (Figure 6).
A complete absence of p65 expression
was observed in all the postmortem
liver biopsy specimens, and p50 expres-
sion was found to be both nuclear as
well as cytoplasmic (Figure 6 C, D). In
contrast, nuclear localization of both p50
and p65 was observed in normal liver
biopsies (Figure 6 A, B).
Partial Participation of p65 in FHF
Patients after Recovery
Although the binding activity of p65
as revealed by band supershift assays
did not show significant differences be-
Figure 2. (A) EMSA using PBMC proteins from the FHF patients, with a 32P-labeled oligonu-
cleotide harboring an NF-kB consensus sequence. Binding specificity was evidenced by
pre-incubation with a 100-fold molar addition of the homologous unlabeled oligonu-
cleotide (lane b) in comparison with competition experiments using a heterologous con-
sensus sequence of the Oct-1 transcription factor (lane c). The squares mark the unspe-
cific complexes. (B) EMSA carried out with labeled oligos encompassing a consensus
sequence of Oct-1 transcription factor showing uniform binding activity in PBMC proteins
from different subjects. Lane a, normal healthy pregnant women as controls (N); lane b,
hepatitis virus infected FHF pregnant patients (F); lane c, PBMC protein of patients who re-
covered back to normalcy (R). The positions of the specific retarded bands are indicated.
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tween pregnant and nonpregnant FHF
patients, the expression of p65 protein in
Western blotting did show low expression
in nonpregnant FHF females (Figure 7,
lane b) similar to that observed in FHF
patients after recovery (Figure 7, lane c).
Of 20 pregnant women with hepatitis
virus-induced FHF, 18 died within 24 h
of their hospital admission. Only two
patients, one infected with HBV and the
other with HEV, recovered following
treatment. Interestingly, when we exam-
ined these women again one month after
their complete recovery, we observed a
moderately elevated level of p65 expres-
sion in these patients (Figure 7, lane c),
although p50 still remained the major
component (Figure 3D, E). A similar
pattern of high binding activity of NF-
kB but a low expression of p65 was
observed in pregnant women with
AVH who served as an additional con-
trol group (see Table 1 and Figure 7,
lane d and e).
DISCUSSION
HBV, HCV, and HEV are considered
the principal etiologic agents for viral
hepatitis and FHF, and extremely high
mortality caused mainly by HEV infec-
tion occurs in Indian pregnant women
Figure 3. Electromobility supershift analysis using nuclear extracts from PBMC of (A) healthy pregnant women without hepatitis virus infection,
(B, C) pregnant FHF patients infected with different hepatitis viruses, and (D,E) FHF patients after their recovery to normalcy, with 32P-labeled
oligonucleotides harboring an NF-kB consensus sequence showing differential binding activity of NF-kB components. PBMC nuclear extracts
were incubated with specific antibodies (Abs) recognizing different members of the NF-kB family. Lane a, without Ab; lane b, addition of p50
Ab; lane c, addition of p65 Ab. The position of the NF-kB specific complex and the additionally retarded complexes is indicated with arrows.
The squares mark the unspecific complexes. The dark circles mark the free oligos. The extent of supershifting as revealed by densitometry
analysis are indicated below each lane and was derived in comparison to the non-shifted NF-kB complex in lane a.
Figure 4. (A) Electromobility supershift analysis using nuclear extracts from liver biopsies of died
pregnant FHF patient, with 32P-labeled oligonucleotides harboring an NF-kB consensus se-
quence showing differential binding activity of NF-kB components. Liver biopsy extracts were
incubated with specific antibodies (Abs) recognizing different members of the NF-kB family.
Lane a, without Ab; lane b, addition of p50 Ab; lane c, addition of p65 Ab. The position of the
NF-kB specific complex is indicated. The arrowheads mark the positions of additionally re-
tarded ‘supershift’ complexes. The squares mark the unspecific complexes. The extent of su-
pershifting as revealed by densitometry analysis are indicated below each lane and was de-
rived in comparison to the non-shifted NF-kB complex in lane a. (B) Differential expression of
p50 and p65 in liver biopsy from pregnant FHF patients who died after being admitted in the
hospital; 30 μg protein from each case was separated in a 10% SDS-PAGE mini gel. After
electrotransfer, the filters were consecutively incubated with p50 and p65 antibodies of NF-kB
family. To confirm, equal protein loading, the filters were reincubated with a polyclonal Actin
antibody. Lanes a, normal healthy pregnant women as disease controls (N); lane b and c,
pregnant FHF patients who died. The increases in expression in comparison to the normal
control as revealed by densitometric analysis are indicated below each lane.
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compared with their nonpregnant coun-
terparts (1,3). This high mortality was
evident in the present study. Out of 20
pregnant FHF patients, 18 (90%) of
which 14 (77.8%) were infected with
HEV died within 24 h of their admission
in the hospital, whereas none of five non-
pregnant women with FHF died. We per-
formed electrophoretic mobility super-
shift assays and immunoblotting using
antibodies against p50 and p65 with the
nuclear extracts prepared from blood
samples as well as liver tissues of dying
FHF patients along with controls. We ob-
served a very high DNA binding activity
of NF-kB in pregnant FHF patients com-
pared with that of healthy controls, but
further dissection of components in
band-supershift assays revealed that in
spite of high binding of NF-kB, the p65
always remained absent in NF-kB com-
plex formation (Figure 3B, C). The com-
plete absence of p65 expression is also
confirmed by immunoblotting (Figure 5).
Thus the major component showing high
DNA binding activity and expression
was p50, which was found to be forming
a homodimer in absence of its canonical
dimerization partner, p65. Interestingly,
the two pregnant FHF patients who re-
ceived treatment and returned to normal
health showed reappearance of p65, al-
though in a low amount, as a het-
erodimerization partner both in gel shift
assay (Figure 3D, E) as well as in im-
munoblotting (Figure 7, lane c). Most in-
terestingly, an inverse correlation be-
tween p65 expression and viral load of
HEV has been observed in pregnant FHF
patients who showed an extremely high
Figure 5. Differential expression of p50 and
p65 in PBMC proteins from pregnant FHF
patients (FHF1 and FHF2). From each pa-
tient, 30 μg of protein was separated in a
10% SDS-PAGE mini gel. After electrotrans-
fer, the filters were consecutively incu-
bated with p50 and p65 antibodies of NF-
kB family. To confirm, equal protein
loading, the filters were reincubated with
a polyclonal Actin antibody. Lanes a, nor-
mal healthy pregnant women as disease
controls (N); lane b and c, pregnant hep-
atitis virus infected FHF patients. The in-
crease in expression in comparison to the
normal control as revealed by densitome-
try analysis is indicated below each lane.
Figure 6. Immunohistochemical analysis of expression and localization of p50 and p65 in
normal as well as post-mortem liver biopsies of FHF patients. Paraffin-embedded sections
(4-5 µm thick) were immunolocalized with the Santa-Cruz antibodies specific for p50 and
p65 of NF-kB. (A) IHC using p50 antibody in normal liver tissue; (B) IHC using p65 antibody
in normal liver tissue; (C) IHC using p50 antibody in postmortem liver biopsy; (D) IHC using
p65 antibody in postmortem liver biopsy.
Figure 7. Comparison of differential expression pattern of p50 and p65 in PBMC proteins
from a non-pregnant FHF (lane b) and a pregnant (lane c) FHF patient who recovered
back to normalcy following treatment and 2 pregnant acute viral hepatitis (AVH) patient
(disease controls) (lane d and e); 30μg proteins from each case was separated in a 10%
SDS-PAGE mini gel. After electrotransfer, the filters were consecutively incubated with p50
and p65 antibodies of NF-kB family. To confirm, equal protein loading, the filters were rein-
cubated with a polyclonal Actin antibody. Lanes a, normal healthy pregnant women as
disease controls (N); lane b, non-pregnant FHF patients; lane c, recovered pregnant FHF
patients. The increase in expression, in comparison to the normal control, as revealed by
densitometry analysis is indicated below each lane.
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titer of viral load compared with that of
pregnant women with AVH or nonpreg-
nant women with FHF (Jilani et al, un-
published data).
In an ingenious experiment by Balti-
more and his group [Beg et al. (14)], it
has been demonstrated that mice lacking
the p65 component of NF-kB show wide-
spread hepatic apoptosis and die at 15-16 d
of embryonic development. Also, experi-
ments done with fibroblasts from 13-day-
old embryos revealed that p65 deficiency
interferes with inducible but not basal
levels of NF-kB activity, and p65 has
been shown to be essential for liver de-
velopment, enhanced cell proliferation,
and liver regeneration. Therefore, NF-kB
is mostly activated after partial hepatec-
tomy. Because the principal factors re-
sponsible for the poor clinical outcome
and high mortality of FHF patients are
severe liver damage, lack of liver regen-
eration, and impaired immunity, our ob-
servation of selective suppression of p65
and an increased homodimerization of
p50 subunits leading to disruption of
normal NF-kB complex and its function
seems to play a crucial role during viral
hepatitis and FHF. This hypothesis gains
credence from our observation of par-
tially upregulated expression of p65 in
two pregnant FHF women who recov-
ered after treatment. It is also important
to note that although there is apparently
no significant difference in increased 
NF-kB binding activity between preg-
nant and nonpregnant FHF patients,
nonpregnant patients did show similarly
moderate to low levels of p65 expression,
as observed in patients who recovered.
Also, an almost similar pattern of high
binding activity of NF-kB but a low ex-
pression of p65 was observed in preg-
nant AVH patients who served as an ad-
ditional disease control group (see Table 1
and Figure 7, lane d and e). Thus our re-
sults establish that the presence of p65 is
most essential, and its absence is respon-
sible for severe liver damage and high
mortality in pregnant FHF patients. This
conclusion gains further support from
the recent observation that decreased
expression of p65 causes liver fibrosis
and liver damage in patients with HCV-
induced chronic liver disease (22).
The expression of transcription factor
NF-kB, which is generally downregu-
lated during pregnancy, was recently
demonstrated to play a pivotal role in
regulating the maternal immune re-
sponses throughout gestation (21). NF-kB
expression also regulates apoptosis of
certain specific cell types through tran-
scriptional control of cell-cycle regula-
tory and other protective genes (23,24),
as is evident from the massive degenera-
tion of liver by apoptosis leading to em-
bryonic lethality in p65 knockout mice.
Recently, McCracken et al (25) have
showed that NF-kB is downregulated in
T-cells during pregnancy, which in turn
Figure 8. Diagrammatic representation of the possible signaling pathways involved in
HEV-induced pathogenesis during pregnancy.
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increases the susceptibility of T-cells to
apoptosis. We found very high NF-kB
activity in pregnant FHF patients, which
may be indicative of highly increased 
T-cell response leading to a severe imbal-
ance in maternal immune responses. It is
well established that T-cell-mediated im-
munity is highly decreased during preg-
nancy owing to marked reduction in 
T-cells and increased B cell counts (26–28).
Recently, low CD4 and high CD8 T-cell
counts and a decreased CD4/CD8 ratio
leading to a low or loss of immunity in
pregnant women was demonstrated (29).
This finding indicates that HEV infection
induces high production of CD8 cells,
which appear to be recognized by spe-
cific viral proteins that are expressed
specifically in liver cells (Figure 8). As is
the case in HCV (30,31) and HBV (32)
infection, the expression of specific HEV
protein can also enhance NF-kB activa-
tion, which modulates immunoregula-
tory molecules and leads to production
of serum and intrahepatic inflammatory
cytokine including TNF-α (31). CD8 cells
that kill hepatocytes may cause degener-
ation of liver and release of cytokines
such as TNF-α, IL-1, and IL-6, which in
turn activate NF-kB in PBMCs, leading
to further release of the above cytokines
(see Figure 8). It is also known that viral
hepatitis and FHF can induce local pro-
duction of proinflammatory cytokines
such as TNF-α, IL-1, and IL-6 (33,34),
which not only activate NF-kB but also
exert effects on liver regeneration and
hepatocyte apoptosis and liver necrosis
(35). In addition, the decreased CD4/
CD8 ratio causes severe immune defi-
ciency in pregnant FHF women. Because
the fetus is also infected through mater-
nal circulation, similar phenomena
occur in fetal liver, which is the site for
development of the immune system.
Therefore both mother and fetus are
equally affected. The growing fetus is
highly susceptible and affected first, and
may die in utero or be aborted, or both
the fetus and mother may die together.
A schematic model showing the possible
signaling pathways involved during
hepatitis virus-induced FHF leading to
death in advanced stage pregnant
women is presented in Figure 8.
In contrast, immune function in the
nonpregnant FHF patients was found
to be much better than in their pregnant
counterparts. A further deterioration
in immune response during advanced
pregnancy, when mortality due to FHF
is significantly higher, may be con-
tributed by selective suppression of p65
and/or disruption of normal NF-kB
complexes.
The immunosuppressive functions of
steroid hormones in lymphocytes are
well documented (36) and are mediated
through interactions between steroid re-
ceptors and NF-kB, leading to inhibition
of NF-kB DNA binding activity. It is par-
adoxical, however, to find a high NF-kB
binding activity but a low cellular immu-
nity in pregnant FHF patients. The for-
mation of NF-kB p50 homodimers,
which also act as repressors of NF-kB–
dependent transcription, and absence of
p65 might explain this finding. Recently,
a similar pattern of homodimerization of
p50 subunits leading to functional inhibi-
tion of NF-kB was reported in laryngeal
papilloma (37) and cervical (38) and oral
carcinoma (39).
The level of sex steroid hormones,
particularly progesterone and estrogens
that are increased during later half of
pregnancy, are also known to directly in-
fluence viral replication and viral gene
expression through their effects on viral
regulatory elements (40–42). Therefore
pregnancy appears to be a potential risk
factor for enhanced viral replication/
expression and along with this extremely
low immunity in Indian/Asian pregnant
women, a vast majority of whom suffer
from malnutrition and folate deficiency
(43), which also contribute to liver injury,
low immunity, and disease severity,
leading to death (see Figure 8). Highly
reduced immunocompetence is known to
be associated with folate deficiency
(43–45), which increases the multiple
viral infection and/or increased viral
load (43), including multifactorial disor-
ders, in the Asian population (46,47). A
selective high susceptibility of Asian
pregnant women to viral hepatitis lead-
ing to liver failure could also be due to
ethnicity-associated host genetic suscepti-
bility, particularly associated with the
genes of the major histocompatibility
complex (MHC), which has a strong ef-
fect on immune response to viral antigens
(48,49). Thus it is possible that a specific
HLA allele(s) or haplotype(s) prevalent in
Indian women might be associated with
severe immune deficiency that influences
the persistence HEV infection.
In conclusion, we suggest that the 
NF-kB signaling pathway is differentially
regulated at the transcriptional level
through upregulation and homodimer-
ization of p50 subunits but selective sup-
pression of its canonical dimerization
partner p65. This suppression correlates
with severe liver damage and complete
breakdown of the immune system, which
leads to multiple organ failure and death
of both the mother and the fetus.
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